Patents by Inventor Andrew Hornby Dobson

Andrew Hornby Dobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds
    Patent number: 10202391
    Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 12, 2019
    Assignee: AstraZeneca AB
    Inventors: Clifford David Jones, Richard Andrew Ward, Mark Andrew Graham, Steven Swallow, Andrew Hornby Dobson, James Francis McCabe
  • Chemical Compounds
    Publication number: 20180237443
    Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 23, 2018
    Applicant: AstraZeneca AB
    Inventors: Clifford David Jones, Richard Andrew Ward, Mark Andrew Graham, Steven Swallow, Andrew Hornby Dobson, James Francis McCabe
  • Chemical compounds
    Patent number: 9902731
    Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 27, 2018
    Assignee: AstraZeneca AB
    Inventors: Clifford David Jones, Richard Andrew Ward, Mark Andrew Graham, Steven Swallow, Andrew Hornby Dobson, James Francis McCabe
  • Chemical Compounds
    Publication number: 20170204100
    Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
    Type: Application
    Filed: November 8, 2016
    Publication date: July 20, 2017
    Applicant: AstraZeneca AB
    Inventors: Clifford David Jones, Richard Andrew Ward, Mark Andrew Graham, Steven Swallow, Andrew Hornby Dobson, James Francis McCabe
  • Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A
    Patent number: 8404839
    Abstract: 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: March 26, 2013
    Assignee: Astrazeneca AB
    Inventor: Andrew Hornby Dobson
  • CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-...
    Publication number: 20120035363
    Abstract: 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: ASTRAZENECA AB
    Inventor: Andrew Hornby Dobson
  • Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
    Patent number: 8088782
    Abstract: 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: January 3, 2012
    Assignee: AstraZeneca AB
    Inventor: Andrew Hornby Dobson
  • SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH
    Publication number: 20110207745
    Abstract: Solid forms comprising salts of 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, compositions comprising the solid forms, methods of making the solid forms, and methods of their use for the treatment of various diseases and/or disorders are provided herein.
    Type: Application
    Filed: November 23, 2010
    Publication date: August 25, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Louis Diorazio, Andrew Hornby Dobson, Alison Norton, Anne O'Kearney-McMullan, Dedong Wu
  • NOVEL SALT-554
    Publication number: 20090286982
    Abstract: 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.
    Type: Application
    Filed: May 11, 2009
    Publication date: November 19, 2009
    Applicant: ASTRAZENECA AB
    Inventor: Andrew Hornby Dobson